The one therapy obtainable for patients with leprechaunism to date is recombinant IGF1, aiming to stop compensatory hyperinsulinemia (23). IGF has with regard to the 6% of your glucose-decreasing motion outcome of insulin and has an analogous framework to it, therefore it will be able to bind to insulin receptors triggering peripheral glucose uptak